Anti-sars-cov-2 antibodies and application thereof
AssigneeNational Defense Medical Center
InventorsSzu-Chia LAI, Yu-Yine Huang, Yi-Ling Chen, Jiunn-Jye Wey, Po-Shiuan Hsieh, Meng-Hung Tsai, Jyh-Hwa Kau
Life of this patent
Estimating the term…
Abstract
The present invention relates to anti-SARS-CoV-2 antibodies and/or antigen-binding fragments thereof, which are useful for specific detection of SARS-CoV-2 in a biological sample. The present invention also provides methods and kits for detecting SARS-CoV-2 and methods and compositions for use in diagnosis and treatment of coronavirus disease (COVID-19) using the anti-SARS-CoV-2 antibodies as described herein.
Claims17
An isolated antibody against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or antigen-binding fragment thereof, wherein the isolated antibody is selected from the group consisting of:
- (i) a first antibody, comprising
- (a) a heavy chain variable region (VH) which comprises a heavy chain complementarity determining region 1 (HC CDR1) of SEQ ID NO:
- 1, a heavy chain complementarity determining region 2 (HC CDR2) of SEQ ID NO:
- 2, and a heavy chain complementarity determining region 3 (HC CDR3) of SEQ ID NO:
- 3;
- and
- (b) a light chain variable region (VL) which comprises a light chain complementarity determining region 1 (LC CDR1) of SEQ ID NO:
- 5, a light chain complementarity determining region 2 (LC CDR2) of SEQ ID NO:
- 6, and a light chain complementarity determining region 3 (LC CDR3) of SEQ ID NO:
- 7;
- and
- (ii) a second antibody, comprising
- (a) a VH which comprises an HC CDR1 of SEQ ID NO:
- 9, an HC CDR2 of SEQ ID NO:
- 10, and an HC CDR3 of SEQ ID NO:
- 11;
- and
- (b) a VL which comprises an LC CDR1 of SEQ ID NO:
- 13, an LC CDR2 of SEQ ID NO:
- 14, and an LC CDR3 of SEQ ID NO:
- 15;
- and
- (iii) a combination of (i) and (ii).
A method for detecting SARS-CoV-2 in a sample suspected of containing said SARS-CoV-2, comprising contacting the sample with an isolated antibody or antigen-binding fragment thereof specific to SARS-CoV-2, and assaying binding of the antibody with the sample, wherein the isolated antibody is selected from the group consisting of:
- (i) a first antibody that comprises a VH comprising an HC CDR1 of SEQ ID NO:
- 1, an HC CDR2 of SEQ ID NO:
- 2, and an HC CDR3 of SEQ ID NO:
- 3;
- and a VL comprising an LC CDR1 of SEQ ID NO:
- 5, an LC CDR2 of SEQ ID NO:
- 6, and an LC CDR3 of SEQ ID NO:
- 7;
- and
- (ii) a second antibody that comprises a VH comprising an HC CDR1 of SEQ ID NO:
- 9, an HC CDR2 of SEQ ID NO:
- 10, and an HC CDR3 of SEQ ID NO:
- 11;
- and a VL comprising an LC CDR1 of SEQ ID NO:
- 13, an LC CDR2 of SEQ ID NO:
- 14, and an LC CDR3 of SEQ ID NO:
- 15;
- and
- (iii) a combination of (i) and (ii).
A kit for detecting the presence of SARS-CoV-2 in a sample, comprising one or more isolated antibodies specific to SARS-CoV-2 or antigen-binding fragment thereof, wherein the isolated antibody is selected from the group consisting of:
- (i) a first antibody that comprises a VH comprising an HC CDR1 of SEQ ID NO:
- 1, an HC CDR2 of SEQ ID NO:
- 2, and an HC CDR3 of SEQ ID NO:
- 3;
- and a VL comprising an LC CDR1 of SEQ ID NO:
- 5, an LC CDR2 of SEQ ID NO:
- 6, and an LC CDR3 of SEQ ID NO:
- 7;
- and
- (ii) a second antibody that comprises a VH comprising an HC CDR1 of SEQ ID NO:
- 9, an HC CDR2 of SEQ ID NO:
- 10, and an HC CDR3 of SEQ ID NO:
- 11;
- and a VL comprising an LC CDR1 of SEQ ID NO:
- 13, an LC CDR2 of SEQ ID NO:
- 14, and an LC CDR3 of SEQ ID NO:
- 15;
- and
- (iii) a combination of (i) and (ii).
Dependencies are inferred from the claim text.